Search

Your search keyword '"Yin, Juanjuan"' showing total 380 results
Start Over Author "Yin, Juanjuan"
380 results on '"Yin, Juanjuan"'

3. A Weakly-Supervised Multi-lesion Segmentation Framework Based on Target-Level Incomplete Annotations

Author

Ju, Jianguo, Ren, Shumin, Qiu, Dandan, Tu, Huijuan, Yin, Juanjuan, Xu, Pengfei, Guan, Ziyu, Goos, Gerhard, Series Editor, Hartmanis, Juris, Founding Editor, Bertino, Elisa, Editorial Board Member, Gao, Wen, Editorial Board Member, Steffen, Bernhard, Editorial Board Member, Yung, Moti, Editorial Board Member, Linguraru, Marius George, editor, Dou, Qi, editor, Feragen, Aasa, editor, Giannarou, Stamatia, editor, Glocker, Ben, editor, Lekadir, Karim, editor, and Schnabel, Julia A., editor

Published
2024
Full Text
View/download PDF

13. Facile Fabrication of LaFeO3 Supported Pd Nanoparticles as Highly Effective Heterogeneous Catalyst for Suzuki–Miyaura Coupling Reaction.

Author

Sun, Ying, Yin, Juanjuan, Wang, Ying, Zhang, Ping, Ma, Lingjuan, and Li, Jisen

Subjects
COUPLING reactions (Chemistry), HETEROGENEOUS catalysis, CATALYST supports, CATALYTIC activity, CATALYSTS
Abstract

Supported Pd catalysts have been widely studied due to their enormous potential as candidates for heterogeneous Suzuki–Miyaura coupling reactions. However, the sintering and low activity of active sites still remain challenges. A vesicle‐shaped LaFeO3‐supported Pd catalyst (I−Pd/LaFeO3) was successfully fabricated using the impregnation method and tested for the Suzuki–Miyaura coupling reaction. Compared to P−Pd/LaFeO3 prepared with photo‐deposition and Pd/Al2O3 prepared with impregnation, the I−Pd/LaFeO3 catalyst exhibits significantly higher catalytic activity, stability, and reusability. The chemical composition and electron states of different Pd‐based catalysts were well studied based on various characterizations and the results indicated that the excellent performance of I−Pd/LaFeO3 can be attributed to its unique nanostructure and the strong interactions between LaFeO3 and palladium nanoparticles. The impregnation method and the choice of the LaFeO3 support show a great influence on the electronic properties of Pd species, their reducibility, and, consequently, their reaction behavior. This unique LaFeO3 supported Pd catalyst provided an environmentally friendly heterogeneous method for the Suzuki–Miyaura coupling reaction. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models

Author

Agarwal, Supreet, Fang, Lei, McGowen, Kerry, Yin, JuanJuan, Bowman, Joel, Ku, Anson T., Alilin, Aian Neil, Corey, Eva, Roudier, Martine P., True, Lawrence D., Dumpit, Ruth, Coleman, Ilsa, Lee, John K., Nelson, Peter S., Capaldo, Brian J., Mariani, Aida, Hoover, Clare, Senatorov, Ilya S., Beshiri, Michael, Sowalsky, Adam G., Hurt, Elaine M., and Kelly, Kathleen

Subjects
United States. National Cancer Institute -- Analysis, AstraZeneca PLC, Biopharmaceutics -- Health aspects -- Analysis, Tumor proteins -- Drug therapy, Prostate cancer -- Drug therapy, Antineoplastic agents -- Health aspects -- Analysis, Metastasis -- Drug therapy, Viral antibodies -- Health aspects -- Analysis, Antigens -- Analysis -- Health aspects, Antibodies -- Health aspects -- Analysis, Biological markers -- Health aspects -- Analysis, Pharmaceutical industry -- Health aspects -- Analysis, Antimitotic agents -- Health aspects -- Analysis, Health care industry
Abstract

Antibody-drug conjugates (ADCs) are a promising targeted cancer therapy; however, patient selection based solely on target antigen expression without consideration for cytotoxic payload vulnerabilities has plateaued clinical benefits. Biomarkers to capture patients who might benefit from specific ADCs have not been systematically determined for any cancer. We present a comprehensive therapeutic and biomarker analysis of a B7H3-ADC with pyrrolobenzodiazepine(PBD) payload in 26 treatment- resistant, metastatic prostate cancer (mPC) models. B7H3 is a tumor-specific surface protein widely expressed in mPC, and PBD is a DNA cross-linking agent. B7H3 expression was necessary but not sufficient for B7H3-PBD-ADC responsiveness. RB1 deficiency and/or replication stress, characteristics of poor prognosis, and conferred sensitivity were associated with complete tumor regression in both neuroendocrine (NEPC) and androgen receptor positive (ARPC) prostate cancer models, even with low B7H3 levels. Non-ARPC models, which are currently lacking efficacious treatment, demonstrated the highest replication stress and were most sensitive to treatment. In RB1 WT ARPC tumors, SLFN11 expression or select DNA repair mutations in SLFN11 nonexpressors governed response. Importantly, WT TP53 predicted nonresponsiveness (7 of 8 models). Overall, biomarker-focused selection of models led to high efficacy of in vivo treatment. These data enable a paradigm shift to biomarker-driven trial designs for maximizing clinical benefit of ADC therapies., Introduction Metastatic prostate cancer (mPC) remains a lethal disease accounting for more than 30,000 deaths annually in the United States (1). The use of androgen deprivation therapy (ADT) and androgen [...]

Published
2023
Full Text
View/download PDF

33. Stem cell dynamics and cellular heterogeneity across lineage subtypes of castrate-resistant prostate cancer.

Author

Beshiri, Michael L, Capaldo, Brian J, Lake, Ross, Ku, Anson T, Burner, Danielle, Tice, Caitlin M, Tran, Crystal, Kostas, Julianna, Alilin, Aian Neil, Yin, JuanJuan, Agarwal, Supreet, Morris, Samantha A, Karzai, Fatima H, Lotan, Tamara L, Dahut, William L, Sowalsky, Adam G, and Kelly, Kathleen

Subjects
PROSTATE cancer, STEM cells, PHENOTYPIC plasticity, HETEROGENEITY, CELL populations, ANDROGEN receptors
Abstract

To resist lineage-dependent therapies such as androgen receptor inhibition, prostate luminal epithelial adenocarcinoma cells often adopt a stem-like state resulting in lineage plasticity and phenotypic heterogeneity. Castrate-resistant prostate adenocarcinoma can transition to neuroendocrine (NE) and occasionally to amphicrine, co-expressed luminal and NE, phenotypes. We developed castrate-resistant prostate cancer (CRPC) patient-derived organoid models that preserve heterogeneity of the originating tumor, including an amphicrine model displaying a range of luminal and NE phenotypes. To gain biological insight and to identify potential treatment targets within heterogeneous tumor cell populations, we assessed the lineage hierarchy and molecular characteristics of various CRPC tumor subpopulations. Transcriptionally similar stem/progenitor (St/Pr) cells were identified for all lineage populations. Lineage tracing in amphicrine CRPC showed that heterogeneity originated from distinct subclones of infrequent St/Pr cells that produced mainly quiescent differentiated amphicrine progeny. By contrast, adenocarcinoma CRPC progeny originated from St/Pr cells and self-renewing differentiated luminal cells. Neuroendocrine prostate cancer (NEPC) was composed almost exclusively of self-renewing St/Pr cells. Amphicrine subpopulations were enriched for secretory luminal, mesenchymal, and enzalutamide treatment persistent signatures that characterize clinical progression. Finally, the amphicrine St/Pr subpopulation was specifically depleted with an AURKA inhibitor, which blocked tumor growth. These data illuminate distinct stem cell (SC) characteristics for subtype-specific CRPC in addition to demonstrating a context for targeting differentiation-competent prostate SCs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Supplementary Materials from A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening

Author

Beshiri, Michael L., primary, Tice, Caitlin M., primary, Tran, Crystal, primary, Nguyen, Holly M., primary, Sowalsky, Adam G., primary, Agarwal, Supreet, primary, Jansson, Keith H., primary, Yang, Qi, primary, McGowen, Kerry M., primary, Yin, JuanJuan, primary, Alilin, Aian Neil, primary, Karzai, Fatima H., primary, Dahut, William L., primary, Corey, Eva, primary, and Kelly, Kathleen, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figures from A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening

Author

Beshiri, Michael L., primary, Tice, Caitlin M., primary, Tran, Crystal, primary, Nguyen, Holly M., primary, Sowalsky, Adam G., primary, Agarwal, Supreet, primary, Jansson, Keith H., primary, Yang, Qi, primary, McGowen, Kerry M., primary, Yin, JuanJuan, primary, Alilin, Aian Neil, primary, Karzai, Fatima H., primary, Dahut, William L., primary, Corey, Eva, primary, and Kelly, Kathleen, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Tables from A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening

Author

Beshiri, Michael L., primary, Tice, Caitlin M., primary, Tran, Crystal, primary, Nguyen, Holly M., primary, Sowalsky, Adam G., primary, Agarwal, Supreet, primary, Jansson, Keith H., primary, Yang, Qi, primary, McGowen, Kerry M., primary, Yin, JuanJuan, primary, Alilin, Aian Neil, primary, Karzai, Fatima H., primary, Dahut, William L., primary, Corey, Eva, primary, and Kelly, Kathleen, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Table 4 from A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening

Author

Beshiri, Michael L., primary, Tice, Caitlin M., primary, Tran, Crystal, primary, Nguyen, Holly M., primary, Sowalsky, Adam G., primary, Agarwal, Supreet, primary, Jansson, Keith H., primary, Yang, Qi, primary, McGowen, Kerry M., primary, Yin, JuanJuan, primary, Alilin, Aian Neil, primary, Karzai, Fatima H., primary, Dahut, William L., primary, Corey, Eva, primary, and Kelly, Kathleen, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results